IL-6 is a cytokine involved in inflammatory reactions, and the IL-6 inhibitory effect of satralizumab suppresses fever symptoms and increase in blood level of C-reactive protein, which poses a risk of delaying the detection of infection. Here, IL6 is linked to infection.